a phase III, randomized, open-label trial evaluating the efficacy of atezolizumab administered concomitantly with bladder instillations of BCG (Bacille Calmette-Guérin) for one year in patients with non-muscle-invasive bladder cancer at high risk of recurrence and who have not been previously treated with BCG. ALBAN
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GCS UNICANCER
- Phase: III
- Execution start: 22/04/2022
- End of execution: 30/01/2028
- IP: MIGUEL ARRABAL MARTIN